New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group

類似資料

• New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group
  著者:: Mariana Bastos‐Oreiro, 等
  出版事項: (2024-04-01)
• Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study
  著者:: Leyre Bento, 等
  出版事項: (2025-07-01)
• Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study
  著者:: Mariana Bastos‐Oreiro, 等
  出版事項: (2025-02-01)
• Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
  著者:: Alejandro Martín García-Sancho, 等
  出版事項: (2022-03-01)
• Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)
  著者:: Francisco-Javier Peñalver, 等
  出版事項: (2017-02-01)